The Efficacy and Safety of Canagliflozin by Frailty Status in Participants of the CANVAS and CREDENCE Trials

Sodium‐glucose cotransporter 2 (SGLT2) inhibitors have been shown to improve renal and cardiovascular outcomes in patients with type 2 diabetes. Limited evidence exists about the efficacy and safety of SGLT2 inhibitors in patients with frailty.

• Publication year

  2025

• Venue

  Journal of The American Geriatrics Society

• Publication date

  2025-03-19

• Fields of study

  Medicine

• Identifiers
  DOI 10.1111/jgs.19444PMID 40105285PMCID 12205298
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The ethics of frailty: a need for consensus guidelines

  2024cited by this paper
• Kidney and Cardiovascular Effects of Canagliflozin According to Age and Sex: A Post Hoc Analysis of the CREDENCE Randomized Clinical Trial.

  2023cited by this paper
• Efficacy and Safety of Dapagliflozin According to Frailty in Patients With Heart Failure: A Prespecified Analysis of the DELIVER Trial

  2022cited by this paper
• Efficacy and Safety of Dapagliflozin According to Frailty in Heart Failure With Reduced Ejection Fraction

  2022cited by this paper
• Haemodynamic Frailty-A Risk Factor for Acute Kidney Injury in the Elderly.

  2021cited by this paper
• Frailty and Biological Age

  2021cited by this paper
• The Impact of Frailty on the Effectiveness and Safety of Intensive Glucose Control and Blood Pressure–Lowering Therapy for People With Type 2 Diabetes: Results From the ADVANCE Trial

  2021cited by this paper
• The prevalence and importance of frailty in heart failure with reduced ejection fraction – an analysis of PARADIGM‐HF and ATMOSPHERE

  2020cited by this paper
• Cardioprotective Effects of Sirtuin-1 and Its Downstream Effectors

  2020cited by this paper
• Sodium‐Glucose Cotransporter 2 Inhibition for the Prevention of Cardiovascular Events in Patients With Type 2 Diabetes Mellitus: A Systematic Review and Meta‐Analysis

  2020cited by this paper
• Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy.

  2019cited by this paper
• SGLT2 inhibition reprograms systemic metabolism via FGF21-dependent and -independent mechanisms.

  2019cited by this paper
• Representativeness of Randomized Clinical Trial Cohorts in End-stage Kidney Disease: A Meta-analysis.

  2019cited by this paper
• The Role of Water Homeostasis in Muscle Function and Frailty: A Review

  2019cited by this paper
• SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis.

  2019cited by this paper
• Sodium-glucose co-transporter 2 inhibitors and cardiovascular outcomes: A systematic review and meta-analysis

  2018cited by this paper
• Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular disease, death and safety outcomes in type 2 diabetes - A systematic review.

  2018influential reference
• Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes

  2017influential reference
• The impact of frailty on coagulation and responses to warfarin in acute older hospitalised patients with atrial fibrillation: a pilot study

  2017cited by this paper
• Sex differences in frailty: A systematic review and meta‐analysis

  2017cited by this paper
• Effect of Frailty and Age on Platelet Aggregation and Response to Aspirin in Older Patients with Atrial Fibrillation: A Pilot Study

  2016cited by this paper
• Development and validation of an electronic frailty index using routine primary care electronic health record data

  2016influential reference
• Sex Differences in Frailty.

  2015cited by this paper
• Frailty in NHANES: Comparing the frailty index and phenotype.

  2015cited by this paper
• Best practice guidelines for the management of frailty: a British Geriatrics Society, Age UK and Royal College of General Practitioners report.

  2014cited by this paper
• Frailty in elderly people.

  2013influential reference
• Frailty is associated with impairment of vaccine-induced antibody response and increase in post-vaccination influenza infection in community-dwelling older adults.

  2011cited by this paper
• Immunological responses to pneumococcal vaccine in frail older people.

  2009cited by this paper
• Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.

  2008influential reference
• A standard procedure for creating a frailty index

  2008cited by this paper
• Efficacy and effectiveness of influenza vaccines in elderly people: a systematic review.

  2005cited by this paper
• Epidemiology 4 Multiplicity in randomised trials I: endpoints and treatments

  2005cited by this paper
• A Meta-Analysis

  year unknowncited by this paper

• Optimizing cardiovascular pharmacotherapy in older adults with frailty.

  2026cites this paper
• Frailty Matters—Why Isn't It Guiding Clinical Decisions?

  2025cites this paper
• REPLY: The Assessment Approach of Frailty May Influence Its Prognostic Impact Amidst Clinical Trials

  2025cites this paper
• The Assessment Approach of Frailty May Influence Its Prognostic Impact Amidst Clinical Trials

  2025cites this paper
• Limitations in Assessing Canagliflozin's Efficacy and Safety in Frail Populations: A Call for Better Frailty Definition

  2025cites this paper
• The use of SGLT2 inhibitors in older people: What is important?

  2025cites this paper